Cargando…
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
PURPOSE: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from addition...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494354/ https://www.ncbi.nlm.nih.gov/pubmed/30860945 http://dx.doi.org/10.1200/JCO.18.01511 |
_version_ | 1783415246650605568 |
---|---|
author | Freedman, Rachel A. Gelman, Rebecca S. Anders, Carey K. Melisko, Michelle E. Parsons, Heather A. Cropp, Anne M. Silvestri, Kelly Cotter, Christine M. Componeschi, Kathryn P. Marte, Juan M. Connolly, Roisin M. Moy, Beverly Van Poznak, Catherine H. Blackwell, Kimberly L. Puhalla, Shannon L. Jankowitz, Rachel C. Smith, Karen L. Ibrahim, Nuhad Moynihan, Timothy J. O’Sullivan, Ciara C. Nangia, Julie Niravath, Polly Tung, Nadine Pohlmann, Paula R. Burns, Robyn Rimawi, Mothaffar F. Krop, Ian E. Wolff, Antonio C. Winer, Eric P. Lin, Nancy U. |
author_facet | Freedman, Rachel A. Gelman, Rebecca S. Anders, Carey K. Melisko, Michelle E. Parsons, Heather A. Cropp, Anne M. Silvestri, Kelly Cotter, Christine M. Componeschi, Kathryn P. Marte, Juan M. Connolly, Roisin M. Moy, Beverly Van Poznak, Catherine H. Blackwell, Kimberly L. Puhalla, Shannon L. Jankowitz, Rachel C. Smith, Karen L. Ibrahim, Nuhad Moynihan, Timothy J. O’Sullivan, Ciara C. Nangia, Julie Niravath, Polly Tung, Nadine Pohlmann, Paula R. Burns, Robyn Rimawi, Mothaffar F. Krop, Ian E. Wolff, Antonio C. Winer, Eric P. Lin, Nancy U. |
author_sort | Freedman, Rachel A. |
collection | PubMed |
description | PURPOSE: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS: Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m(2) twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS: Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). CONCLUSION: Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted. |
format | Online Article Text |
id | pubmed-6494354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-64943542019-11-20 TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases Freedman, Rachel A. Gelman, Rebecca S. Anders, Carey K. Melisko, Michelle E. Parsons, Heather A. Cropp, Anne M. Silvestri, Kelly Cotter, Christine M. Componeschi, Kathryn P. Marte, Juan M. Connolly, Roisin M. Moy, Beverly Van Poznak, Catherine H. Blackwell, Kimberly L. Puhalla, Shannon L. Jankowitz, Rachel C. Smith, Karen L. Ibrahim, Nuhad Moynihan, Timothy J. O’Sullivan, Ciara C. Nangia, Julie Niravath, Polly Tung, Nadine Pohlmann, Paula R. Burns, Robyn Rimawi, Mothaffar F. Krop, Ian E. Wolff, Antonio C. Winer, Eric P. Lin, Nancy U. J Clin Oncol ORIGINAL REPORTS PURPOSE: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS: Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m(2) twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS: Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). CONCLUSION: Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted. American Society of Clinical Oncology 2019-05-01 2019-03-12 /pmc/articles/PMC6494354/ /pubmed/30860945 http://dx.doi.org/10.1200/JCO.18.01511 Text en © 2019 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | ORIGINAL REPORTS Freedman, Rachel A. Gelman, Rebecca S. Anders, Carey K. Melisko, Michelle E. Parsons, Heather A. Cropp, Anne M. Silvestri, Kelly Cotter, Christine M. Componeschi, Kathryn P. Marte, Juan M. Connolly, Roisin M. Moy, Beverly Van Poznak, Catherine H. Blackwell, Kimberly L. Puhalla, Shannon L. Jankowitz, Rachel C. Smith, Karen L. Ibrahim, Nuhad Moynihan, Timothy J. O’Sullivan, Ciara C. Nangia, Julie Niravath, Polly Tung, Nadine Pohlmann, Paula R. Burns, Robyn Rimawi, Mothaffar F. Krop, Ian E. Wolff, Antonio C. Winer, Eric P. Lin, Nancy U. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases |
title | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases |
title_full | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases |
title_fullStr | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases |
title_full_unstemmed | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases |
title_short | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases |
title_sort | tbcrc 022: a phase ii trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494354/ https://www.ncbi.nlm.nih.gov/pubmed/30860945 http://dx.doi.org/10.1200/JCO.18.01511 |
work_keys_str_mv | AT freedmanrachela tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT gelmanrebeccas tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT anderscareyk tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT meliskomichellee tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT parsonsheathera tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT croppannem tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT silvestrikelly tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT cotterchristinem tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT componeschikathrynp tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT martejuanm tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT connollyroisinm tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT moybeverly tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT vanpoznakcatherineh tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT blackwellkimberlyl tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT puhallashannonl tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT jankowitzrachelc tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT smithkarenl tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT ibrahimnuhad tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT moynihantimothyj tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT osullivanciarac tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT nangiajulie tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT niravathpolly tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT tungnadine tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT pohlmannpaular tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT burnsrobyn tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT rimawimothaffarf tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT kropiane tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT wolffantonioc tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT winerericp tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT linnancyu tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases AT tbcrc022aphaseiitrialofneratinibandcapecitabineforpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerandbrainmetastases |